- £8.34m
- £6.87m
- £5.77m
- 16
- 37
- 61
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.88 | ||
| Price to Tang. Book | 2.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.4% | ||
| Return on Equity | -19.15% | ||
| Operating Margin | -37.36% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 9.53 | 9.19 | 8.64 | 6.67 | 5.77 | 6 | n/a | -5.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +117.33 | +49.5 | -30.44 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
Directors
- Charles Spicer NEC (51)
- Giulio Cerroni CEO (59)
- Grant Nash CFO (44)
- John Bradshaw NED
- Katherine Rogers NED (55)
- Mark Warne NID (45)
- Last Annual
- September 30th, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- November 28th, 1995
- Public Since
- September 4th, 2013
- No. of Employees
- 81
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 92,668,598
- Address
- 4th Fl, Griffin Court, 15 Long Lane, LONDON, EC1A 9PN
- Web
- https://ixico.com/
- Phone
- +44 2037637499
- Auditors
- Grant Thornton UK LLP
Latest News for IXI
Upcoming Events for IXI
Half Year 2025 IXICO PLC Earnings Release
Similar to IXI
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 21:24 UTC, shares in IXICO are trading at 9.00p. This share price information is delayed by 15 minutes.
Shares in IXICO last closed at 9.00p and the price had moved by +2.86% over the past 365 days. In terms of relative price strength the IXICO share price has underperformed the FTSE All Share Index by -1.18% over the past year.
The overall consensus recommendation for IXICO is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIXICO does not currently pay a dividend.
IXICO does not currently pay a dividend.
IXICO does not currently pay a dividend.
To buy shares in IXICO you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 9.00p, shares in IXICO had a market capitalisation of £8.34m.
Here are the trading details for IXICO:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: IXI
Based on an overall assessment of its quality, value and momentum IXICO is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in IXICO is 24.00p. That is 166.67% above the last closing price of 9.00p.
Analysts covering IXICO currently have a consensus Earnings Per Share (EPS) forecast of -£0.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IXICO. Over the past six months, its share price has underperformed the FTSE All Share Index by -3.74%.
As of the last closing price of 9.00p, shares in IXICO were trading -7.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The IXICO PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 9.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
IXICO's management team is headed by:
- Charles Spicer - NEC
- Giulio Cerroni - CEO
- Grant Nash - CFO
- John Bradshaw - NED
- Katherine Rogers - NED
- Mark Warne - NID